Bristol-Myers Squibb (BMY) Tops Q1 EPS by 23c, Affirms EPS Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $1.72, $0.23 better than the analyst estimate of $1.49. Revenue for the quarter came in at $10.8 billion versus the consensus estimate of $10.02 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2020 EPS of $6.00-$6.20, versus the consensus of $6.17. Bristol-Myers Squibb sees FY2020 revenue of $40-42 billion, versus the consensus of $41.65 billion.

• Bristol Myers Squibb is updating its 2020 GAAP EPS guidance range from $0.75 - $0.95 to $0.37 to $0.57. In addition, the company is affirming its 2020 non-GAAP EPS guidance range of $6.00 to $6.20 and 2021 non-GAAP EPS guidance range of $7.15 to $7.45.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Bristol-Myers Squibb Co. (BMY) PT Raised to $82 at Piper Sandler
• Faeth Therapeutics adds cancer biologist Karen Vousden to its board
• Westinghouse said to seek over $50 billion valuation in planned IPO